Prospective, Single-Arm Trial Evaluating Changes in Uptake Patterns on Prostate-Specific Membrane Antigen–Targeted <sup>18</sup>F-DCFPyL PET/CT in Patients with Castration-Resistant Prostate Cancer Starting Abiraterone or Enzalutamide
Katherine Zukotynski(Unknown), Steven P. Rowe(Johns Hopkins Medicine), Amanda L. Blackford(Johns Hopkins University), Anil Kapoor(People’s University), Wei Fu(Johns Hopkins University), Chun K. Kim(Harvard University Press), Emmanuel S. Antonarakis(University of Minnesota), John F. Valliant(McMaster University), Steve Y. Cho(University of Wisconsin–Madison), François Bénard(BC Cancer Agency), Mark C. Markowski(Johns Hopkins University), Martin G. Pomper(Southwestern Medical Center), Sebastién J. Hotte(Juravinski Cancer Centre), Michael A. Gorin(Johns Hopkins University), Kenneth J. Pienta(Johns Hopkins University), Matthew Lubanovic(McMaster University), Urban Emmenegger(Sunnybrook Health Science Centre), Mario A. Eisenberger(Johns Hopkins University)
Cited by 52
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
|Nature Genetics|2013|1.2k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k